Skip to main content

Peer Review reports

From: ‘DURVIT’: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment

Original Submission
21 Nov 2017 Submitted Original manuscript
13 Dec 2017 Author responded Author comments - Jossie Rotman
Resubmission - Version 2
13 Dec 2017 Submitted Manuscript version 2
18 Apr 2018 Reviewed Reviewer Report - Peter van Dam
20 May 2018 Reviewed Reviewer Report - Megan Huchko
19 Jun 2018 Author responded Author comments - Jossie Rotman
Resubmission - Version 3
19 Jun 2018 Submitted Manuscript version 3
21 Jun 2018 Reviewed Reviewer Report - Peter van Dam
16 Jul 2018 Reviewed Reviewer Report - Reviewer 2
2 Aug 2018 Author responded Author comments - Jossie Rotman
Resubmission - Version 4
2 Aug 2018 Submitted Manuscript version 4
Publishing
20 Aug 2018 Editorially accepted
12 Sep 2018 Article published 10.1186/s12885-018-4764-0

You can find further information about peer review here.

Back to article page